about
Baclofen for alcohol withdrawalIntrathecal baclofen for treating spasticity in children with cerebral palsyBaclofen for alcohol withdrawalPharmacological interventions other than botulinum toxin for spasticity after strokeBaclofen for alcohol withdrawalBaclofen for alcohol withdrawalIntrathecal baclofen for treating spasticity in children with cerebral palsyLong-term drug treatment of patients with alcohol dependenceRecovery of neuronal and network excitability after spinal cord injury and implications for spasticityNovel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulationEffects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenilRecovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors.Baclofen neurotoxicity [correction of unerotoxicity] in a chronic haemodialysis patient.Pharmacotherapy of spasticity: oral medications and intrathecal baclofen.Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review.Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician.Intrathecal baclofen for severe spasticity secondary to spinal cord injury.Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.Alcoholic liver disease: treatmentγ-Aminobutyric acid (GABA) signalling in plants.The effects of the muscle relaxant, CS-722, on synaptic activity of cultured neuronesHow many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review.Long-Term Sequelae of Stroke: How should you handle stroke complications?Intermittent hypoxia and neurorehabilitation.Cerebral palsy: comprehensive review and update.Managing advanced multiple sclerosisReduction of spinal sensory transmission by facilitation of 5-HT1B/D receptors in noninjured and spinal cord-injured humans.Fractional anisotropy in children with dystonia or spasticity correlates with the selection for DBS or ITB movement disorder surgery.Low-dose baclofen therapy raised plasma insulin-like growth factor-1 concentrations, but not into the normal range in a predictable and sustained manner in men with chronic spinal cord injury.Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infectionManagement of alcohol dependence in patients with liver disease.KASL clinical practice guidelines: management of alcoholic liver diseaseAnoctamin 1 mediates thermal pain as a heat sensor.Current pharmacological treatment approaches for alcohol dependence.Baclofen for alcohol withdrawal.Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria.Pharmacologic management of non-neurogenic functional obstruction in women.
P2860
Q24186628-7936EAE4-F2D1-45DC-805F-CF8B3E42BCEFQ24187762-4E4FB665-41C9-4129-B706-F23244670A4AQ24200724-A102E066-DA1B-4381-9C9B-97A4E1B00EDBQ24201130-6FED181B-B906-420C-8A0D-335A2C223F66Q24234933-86DF9646-8C15-4D85-A6EC-DBB5FA4B877AQ24235642-3EC9F3C3-61DE-4B86-A210-1D21F8223DB2Q24247608-9B20A1D7-544A-4372-8957-4802E7EB09C8Q26773332-120AA8F1-A371-48C3-BE71-22EE0A2F95E7Q26825721-7CA36E42-7123-4B9D-88F3-D76382583638Q26853630-D0A93AC1-4E3F-4142-AB6E-A7A75F3CCE31Q28368896-EA7EA532-EF8C-432B-9A47-2A63F54E4CCCQ30500846-5219A8CD-8C75-41DD-812C-B01A118BDFF0Q31373043-28273C04-16D5-47A9-9BB5-A9A088068D1DQ32064749-69F5ECE8-9239-41A6-96F8-6CB8BC66A29BQ33582063-FE5882A1-4E10-4EF3-9D64-42E571B1E7F8Q33628003-1CBF93B1-B1BE-47D7-AD61-4F00BE1026F3Q33920110-394BA284-A7A4-49EB-8FA2-7835727B611FQ33983758-C7E375B5-AA7F-45B1-9E98-EDF0726DCF28Q34061347-9F97C305-BB4A-4177-B799-E82DC05963DEQ34091721-33B19B92-3DB8-40B4-ADAC-2169312664BAQ34255479-5723CA56-36EA-41D2-B51A-D27B87DBEE1FQ34544540-3F7FAB55-F8E2-4B14-825A-EDF5C74C2FCAQ35884493-58417D22-6593-43B1-BD2E-E66EA07B28C5Q36059288-283E64CF-68F8-4365-B371-EBA6F4930081Q36283350-459BC39E-923E-4E58-AE0F-0440F264D542Q36382232-F3B73554-9CDA-41A9-ACA7-0F5B476307B9Q36500376-0F84E54F-3CB9-425E-B6DE-7E8C01D94C7BQ36652403-45ACF1EB-7604-45C7-9147-2A3F631FC8D6Q36700713-DC6F4944-C570-4ECD-AD85-1BA4DE6B96F5Q36762395-EE6D91B0-C22E-478A-8363-9F183FDEEFBBQ37085950-A6AA8E03-01EF-45F8-AC49-2C7F445817ADQ37156172-40158D66-8192-43F4-A9AE-38CB8D52308BQ37165425-5B8A774A-6724-46F8-868B-41F7D0BAFD52Q37229858-05156B8E-C492-4CB3-8AAA-6E12BCAA9AB4Q37362045-7635A335-E9BE-4483-921C-E0BF486AB8F5Q38181213-DD2EE623-32FC-4006-A15E-FE37556594C4Q38617705-24125DA8-CBE4-48C6-AB27-31C43CD77599Q38620497-868D3855-F16B-412F-825E-025021D424A2Q38793887-AA8E19D2-9E56-4A31-9C95-712380EF20B1Q38812355-DCFF2147-30F0-4B4A-858C-E0ED92EEC43F
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Antispasticity drugs: mechanisms of action.
@en
Antispasticity drugs: mechanisms of action.
@nl
type
label
Antispasticity drugs: mechanisms of action.
@en
Antispasticity drugs: mechanisms of action.
@nl
prefLabel
Antispasticity drugs: mechanisms of action.
@en
Antispasticity drugs: mechanisms of action.
@nl
P2860
P356
P1433
P1476
Antispasticity drugs: mechanisms of action.
@en
P2093
Davidoff RA
P2860
P304
P356
10.1002/ANA.410170202
P577
1985-02-01T00:00:00Z